Avideh Nazeri is an Iranian endocrinologist who is director of clinical, medical, and regulatory for Novo Nordisk UK and Ireland.
Avideh Nazeri | |
|---|---|
| Alma mater | King's College London |
| Employer | Novo Nordisk |
| Known for | Medicine Pharmaceutical Science |
Education
editNazeri dreamed of becoming an air hostess as a child, but was encouraged by a teacher to study medicine.[1] She trained in medicine at King's College London GKT School of Medical Education.[2]
Career
editIn 2008 Nazeri joined Novo Nordisk in Iran, before working in their global affairs department in Denmark. As global medical director she was in charge of the research portfolio on modern insulins aspart and semaglutide.[2] In 2013 Nazeri became head of medical affairs in Canada, where she launched KOL[clarification needed] engagement and learning programmes within their medical affairs group. In October 2016 Nazeri was appointed as a director of Novo Nordisk[2][3] and worked to build partnerships and drive innovation.[4]
Nazeri has expressed concern about the lack of awareness around the health risks of diabetes mellitus type 2, especially with regards to the development of cardiovascular disease.[5] In 2017 Nazeri urged the public to return faulty insulin cartridge holders in the NovoPen Echo and NovoPen 5 devices, which were found to break when exposed to household cleaning agents.[6][7] Under her leadership, the organisation has expanded treatment options for patients with diabetes.[8] It was reported that Novo Nordisk's insulin degludec was the most cost-effective diabetic treatment.[9] She launched Fiasp, a new fast acting insulin, which improves blood sugar levels after meals by working twice as quickly in the bloodstream.[10]
Nazeri has contributed to Pharmaceutical Journal.[11]
References
edit- ^ Briggs, Helen (2018-03-18). "Breaking the mould in a male-dominated industry". BBC News. Retrieved 2018-03-18.
- ^ a b c "Pharmaceutical Field - Nazeri is new Novo Nordisk Director". www.pharmafield.co.uk. Archived from the original on 2018-03-19. Retrieved 2018-03-18.
- ^ "Pf Magazine November 2016". Issuu. Retrieved 2018-03-18.
- ^ "Novo Nordisk's Avideh Nazeri discusses how a century's heritage remains relevant in such a competitive and fast-changing space". The Pharma Letter. Retrieved 2018-03-18.
- ^ ""Lack of understanding" could put around half of people with type 2 diabetes at risk of heart disease". Diabetes Research & Wellness Foundation. 2017-12-21. Retrieved 2018-03-18.
- ^ "Insulin pens: NovoPen Echo and NovoPen 5 (certain batches) – risk of hyperglycaemia due to cartridge holder weakening when exposed to certain household chemicals". www.gov.uk. Retrieved 2018-03-18.
- ^ "Faulty insulin cartridge holders are recalled - The Diabetes Times". The Diabetes Times. 2017-07-05. Retrieved 2018-03-18.
- ^ "Novo Nordisk's diabetes drug recommended for expanded indication in Europe". www.pharmafile.com. John Wiley & Sons. Retrieved 2018-03-18.
- ^ "New economic data finds Novo Nordisk's insulin degludec most cost effective diabetic treatment". www.europeanpharmaceuticalreview.com. Retrieved 2018-03-18.
- ^ "New faster-acting insulin Fiasp now available in the UK - diabetesgeneeskunde.nl". diabetesgeneeskunde.nl (in Dutch). 2017-04-11. Retrieved 2018-03-18.
- ^ "Avideh Nazeri | Contributor | Pharmaceutical Journal". www.pharmaceutical-journal.com. Retrieved 2018-03-18.